CLINTREX® Overview
CLINTREX is a clinical research company that works with pharmaceutical organizations to operationalize development pathways for new treatments for CNS diseases. CLINTREX incorporates an integrated team of internationally-renowned experts who work collaboratively with members of your organization in order to identify, clarify, and solve pre-clinical, clinical trial, biostatistical, and regulatory issues essential to product development and approval.
Our goal is to provide practical, effective, and efficient solutions that solve problems and take your development ideas from concept to reality.
The CLINTREX team utilizes its experts with disease-specific knowledge, with a particular emphasis on neurodegenerative diseases (eg AD, PD, HD), MS, epilepsy, and migraine, to help you design clinical trials and address regulatory issues. We can work with you to solve a specific regulatory or clinical problem, coordinate with your CRO to enhance the quality of your clinical trial, independently operationalize small studies, and even integrate into and function as part of your senior management team.
We utilize our reputations in the international community, and the “SMART CLINICAL TRIALS” approach to conduct clinical studies that minimize variability, facilitate recruitment, require smaller sample sizes, and increase the likelihood of accurately detecting an accurate and reliable result.
Experience
CLINTREX has provided advisory services and assistance to more than 150 pharmaceutical and biotech companies engaged in the development of new therapies for CNS disorders, and over 60% of these companies engage with us again. Clintrex principals have led clinical trials evaluating pharmaceutical agents, small molecules, devices, and biologics (e.g., transplantation and gene therapy) that have resulted in the approval of multiple therapies for various neurological disorders.
Experience
CLINTREX has provided advisory services and assistance to more than 150 pharmaceutical and biotech companies engaged in the development of new therapies for CNS disorders, and over 60% of these companies engage with us again. Clintrex principals have led clinical trials evaluating pharmaceutical agents, small molecules, devices, and biologics (e.g., transplantation and gene therapy) that have resulted in the approval of multiple therapies for various neurological disorders.
Call us today at 585-355-5341 or Send Us an Email